Literature DB >> 22851162

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Lambertus A Peletier1, Johan Gabrielsson.   

Abstract

In this paper we present a mathematical analysis of the basic model for target mediated drug disposition (TMDD). Assuming high affinity of ligand to target, we give a qualitative characterisation of ligand versus time graphs for different dosing regimes and derive accurate analytic approximations of different phases in the temporal behaviour of the system. These approximations are used to estimate model parameters, give analytical approximations of such quantities as area under the ligand curve and clearance. We formulate conditions under which a suitably chosen Michaelis-Menten model provides a good approximation of the full TMDD-model over a specified time interval.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851162      PMCID: PMC3446204          DOI: 10.1007/s10928-012-9260-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  Impact of plasma-protein binding on receptor occupancy: an analytical description.

Authors:  Lambertus A Peletier; Neil Benson; Piet H van der Graaf
Journal:  J Theor Biol       Date:  2008-10-02       Impact factor: 2.691

2.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

3.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

Review 4.  Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body.

Authors:  Y Sugiyama; M Hanano
Journal:  Pharm Res       Date:  1989-03       Impact factor: 4.200

5.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

6.  On the validity of the steady state assumption of enzyme kinetics.

Authors:  L A Segel
Journal:  Bull Math Biol       Date:  1988       Impact factor: 1.758

Review 7.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

8.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

9.  Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.

Authors:  Wojciech Krzyzanski; Elzbieta Wyska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-11       Impact factor: 3.000

10.  Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis.

Authors:  Ben-Fillippo Krippendorff; Katharina Kuester; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

View more
  39 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

Review 2.  Pattern Recognition in Pharmacokinetic Data Analysis.

Authors:  Johan Gabrielsson; Bernd Meibohm; Daniel Weiner
Journal:  AAPS J       Date:  2015-09-03       Impact factor: 4.009

3.  A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.

Authors:  Rena J Eudy; Matthew M Riggs; Marc R Gastonguay
Journal:  AAPS J       Date:  2015-06-16       Impact factor: 4.009

4.  Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.

Authors:  Gilbert Koch; William J Jusko; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-10       Impact factor: 2.745

5.  Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2017-01-31       Impact factor: 4.009

6.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

7.  Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2018-09-12       Impact factor: 4.009

8.  Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology.

Authors:  Neil Benson; Piet H van der Graaf; Lambertus A Peletier
Journal:  J Math Biol       Date:  2012-12-02       Impact factor: 2.259

Review 9.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

10.  An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.

Authors:  Kwang-Hee Shin; Kyoung Soo Lim; Howard Lee; In-Jin Jang; Kyung-Sang Yu
Journal:  Invest New Drugs       Date:  2014-01-28       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.